Neogen Chemicals Limited moves to reshape its capital structure

The exact rupee split cannot be established from the cited placement-document disclosure. The stated purposes are expansion of Neogen Ionics, working-capital requirements and other strategic initiatives ^[1], while secondary reporting says management intended the raise to primarily support debt reduction ^[2]. An object-wise allocation between debt repayment, working capital and capex is not reproduced, so assigning specific amounts would be unsupported.

Net debt-to-equity impact

The latest structured quarterly figures are consolidated Q1 FY27: net debt of Rs 1,325.00 Crores, total equity of Rs 816.25 Crores and net debt-to-equity of 1.62x ^{[3] [4] [5]}.

Let:

• `D` = proceeds used for debt repayment
• `W` = working capital allocation
• `C` = capex allocation
• `D + W + C = Rs 600 Crores`

Assuming the full Rs 600 Crores is raised as equity, no issue-cost adjustment, and no additional borrowing:

Post-issue net debt-to-equity = (Rs 1,325 Crores − D) / (Rs 816.25 Crores + Rs 600 Crores)

† Derived from the Q1 FY27 net debt and equity figures above; assumes no issue expenses, taxes, fresh borrowing or change in equity other than the Rs 600 Crores raise.

Implication: the raise mechanically strengthens the denominator, but the direct deleveraging benefit depends on `D`, the debt-repayment portion. If most proceeds fund capex and working capital, the immediate improvement in net debt is materially smaller than the 1.62x-to-0.51x theoretical maximum. The exact post-issue ratio therefore requires the placement document’s object-wise amounts and confirmation of actual deployment.

The final QIP issue price was Rs 2,255 per equity share. The company allotted 2,660,753 new shares, increasing total paid-up shares to 30,042,427.^[6]

Dilution calculation: 2,660,753 ÷ 30,042,427 × 100 = 8.86%

Thus, existing shareholders’ aggregate ownership was diluted by approximately 8.86% on a post-issue equity basis; their combined stake falls to approximately 91.14%.

Verdict: The Rs 600 crore QIP was timed near the end of Neogen’s heavy battery-materials investment phase—after most project spending had already occurred but before the Dahej and Pakhajan facilities were scheduled for completion. It is therefore better viewed as a late-cycle funding and balance-sheet reset, rather than primary funding for the entire capex programme. Even after the raise, Neogen’s leverage would remain materially above the specified specialty-chemical peer median unless most proceeds are applied to debt repayment.

Capex timing and scale

Neogen’s disclosed Dahej Phase 1 and Pakhajan Phase 2 battery-materials projects have a combined estimated cost of Rs 1,795 crore. By Q1 FY27, cumulative spending was reported at Rs 1,298 crore, leaving approximately Rs 497 crore of indicated project cost. Dahej was targeted for completion by February 2027 and Pakhajan by March 2027; electrolyte projects were scheduled for H1 FY27 completion and electrolyte-salt projects for H2 FY27. ^[7]

The timing is strategically coherent: the raise came during the final commissioning and ramp-up window, when working capital, trial production and customer qualification can absorb cash. However, because the stated use includes debt repayment and other corporate purposes, the full Rs 600 crore should not be treated as incremental facility capex funding.

Leverage versus peers

Neogen’s consolidated Q1 FY27 gross debt was Rs 1,329.9 crore and its reported debt-to-equity ratio was 1.63x. ^{[10] [11]} For a clean same-period comparison, the table below uses consolidated Q4 FY26 debt-to-equity ratios across the specified peer basket.

Mechanically, using Neogen’s reported debt of Rs 1,329.9 crore and 1.63x debt-to-equity implies equity of approximately Rs 815.9 crore. ^{[10] [11]}

• If the entire gross QIP proceeds were retained as equity and no debt were repaid: pro forma debt-to-equity would be approximately 0.94x.
• If the entire Rs 600 crore were used to repay debt: pro forma debt would be approximately Rs 729.9 crore and debt-to-equity would fall to approximately 0.52x.
• These are illustrative gross-proceeds scenarios; actual leverage will depend on issue costs, the debt-prepayment amount, working-capital deployment and any further borrowing.

Thus, the QIP could reduce Neogen’s reported 1.63x leverage substantially, but the resulting range of approximately 0.52x-0.94x would still be around 9-16 times the peer median of 0.06x. The key balance-sheet question is therefore not whether the raise improves leverage—it should—but how much of the proceeds is actually used for debt reduction rather than funding the final commissioning and working-capital cycle.